Advertisement

Hepatology International

, Volume 11, Issue 2, pp 143–147 | Cite as

Existence of cancer stem cells in hepatocellular carcinoma: myth or reality?

  • Keigo MachidaEmail author
Point of View

Abstract

The cancer stem cell (CSC) hypothesis has been disproved in many cancers. CSCs may exist in blood cancer, while many epithelial cancers may not have CSCs but tumor-initiating cells (TICs). Several independent studies have provided strong evidence for existence of CSCs in brain, skin, and colon cancers (Mani et al. in Cell 133:704–715, 2008, Joseph et al. in Cancer Cell 13:129–140, 2008, Reya et al. in Nature 414:105–111, 2001), while the CSC hypothesis remains controversial (Magee et al. in Cancer Cell 21:283–296, 2012). Liver TICs have bipotential to give rise to two different lineage types: hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). In the liver cancer field, the origin of HCC and CC is extensively debated. Several groups have validated that TICs gave rise to HCC and CC. Hepatocytes gave rise to HCC. Several groups have demonstrated that oval cells (or liver progenitor cells) give rise to TICs. However, CSCs may be a myth in gastrointestinal cancer, while many groups have validated liver TICs. The definition of CSCs includes pluripotency, while TICs do not have to have pluripotency and only need to have bi- or multipotential to give rise to diverse tumor types and tumor initiation potential in mouse models. The CSC hypothesis therefore controversial (Magee et al. in Cancer Cell 21:283–296, 2012). Cancer tissues contain subpopulations of cells known as tumor-initiating stem-like cells (TICs, so-called CSCs) that have been identified as key drivers of tumor growth and malignant progression with drug resistance. Stem cells proliferate via self-renewing division in which the two daughter cells differ in proliferative potential, with one displaying differentiated phenotype and the other retaining self-renewing activity.

Keywords

Liver Tumor-initiating stem-like cells (TICs) Cancer stem cells (CSCs) Hepatitis C virus (HCV) Hepatitis B virus (HBV) 

Notes

Acknowledgements

I thank Mr. Peleg Winer at USC for critical reading. This research was supported by NIH grants 1R01AA018857-01, pilot project funding (5P30DK048522-13), P50AA11999 (Animal Core, Morphology Core, and Pilot Project Program), R24AA012885 (Non-Parenchymal Liver Cell Core), the Cell and Tissue Imaging Core of the USC Research Center for Liver Diseases (P30 DK048522), CA123328, and CA108302. This research is also supported by a Research Scholar Grant (RSG MPC122545) and pilot funding (IRG-58-007-48) from the American Cancer Society. Animal imaging was performed by the USC Molecular Imaging Center supported by NIH/NVRR S10.

Compliance with ethical standards

Conflict of interest

The author declares no conflict of interests.

References

  1. 1.
    Mani SA, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–715Google Scholar
  2. 2.
    Joseph NM, et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008;13:129–140. doi: 10.1016/j.ccr.2008.01.003
  3. 3.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111. doi: 10.1038/35102167
  4. 4.
    Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283–296. doi: 10.1016/j.ccr.2012.03.003
  5. 5.
    Kim J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010;143:313–324. doi: 10.1016/j.cell.2010.09.010 (S0092-8674(10)01058-5[pii])
  6. 6.
    Ikushima H, et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 2011;286:41434–41441. doi: 10.1074/jbc.M111.300863 (M111.300863[pii])
  7. 7.
    Chen J, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522–526. doi: 10.1038/nature11287
  8. 8.
    Kiel MJ, et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 2007;449:238–242Google Scholar
  9. 9.
    Chen CL, et al. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. J Clin Invest 2013;123:2832–2849. doi: 10.1172/JCI65859
  10. 10.
    Ma S, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542–2556Google Scholar
  11. 11.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–3988Google Scholar
  12. 12.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737Google Scholar
  13. 13.
    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–10951Google Scholar
  14. 14.
    Craig CE, et al. The histopathology of regeneration in massive hepatic necrosis. Semin Liver Dis 2004;24:49–64Google Scholar
  15. 15.
    Yang ZF, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008;13:153–166Google Scholar
  16. 16.
    Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749–1758Google Scholar
  17. 17.
    Wurmbach E, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938–947Google Scholar
  18. 18.
    Yeoh GC, et al. Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology 2007;45:486–494Google Scholar
  19. 19.
    Dando JS, et al. Notch/Delta4 interaction in human embryonic liver CD34+ CD38− cells: positive influence on BFU-E production and LTC-IC potential maintenance. Stem Cells 2005;23:550–560Google Scholar
  20. 20.
    Sicklick JK, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006;27:748–757Google Scholar
  21. 21.
    Sicklick JK, et al. Hedgehog signaling maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver Physiol 2006;290:G859–G870Google Scholar
  22. 22.
    Kitisin K, et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 2007;26:7103–7110Google Scholar
  23. 23.
    Nguyen LN, et al. Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. Hepatology 2007;45:31–41Google Scholar
  24. 24.
    Ho JW, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006;44:836–843Google Scholar
  25. 25.
    Singh SK, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401Google Scholar
  26. 26.
    Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005;37:715–719Google Scholar
  27. 27.
    Rountree CB, Senadheera S, Mato JM, Crooks GM, Lu SC. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 2008;47:1288–1297Google Scholar
  28. 28.
    Tirnitz-Parker JE, Tonkin JN, Knight B, Olynyk JK, Yeoh GC. Isolation, culture and immortalisation of hepatic oval cells from adult mice fed a choline-deficient, ethionine-supplemented diet. Int J Biochem Cell Biol 2007;39:2226–2239Google Scholar
  29. 29.
    Libbrecht L, et al. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol 2001;25:1388–1396Google Scholar
  30. 30.
    Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645–648Google Scholar
  31. 31.
    Chiba T, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240–251Google Scholar
  32. 32.
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350–355Google Scholar
  33. 33.
    Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225–237Google Scholar
  34. 34.
    Okuda M, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366–375Google Scholar
  35. 35.
    Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol 2001;2:473–483Google Scholar
  36. 36.
    Oshita M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115–1120Google Scholar
  37. 37.
    Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A 2012;109:829–834Google Scholar
  38. 38.
    Schepers AG, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012;337:730–735. doi: 10.1126/science.1224676
  39. 39.
    Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012;488:527–530. doi: 10.1038/nature11344
  40. 40.
    Chen CL, et al. NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab 2016;23:206–219. doi: 10.1016/j.cmet.2015.12.004
  41. 41.
    Uthaya Kumar DB, et al. TLR4 signaling via NANOG cooperates with STAT3 to activate Twist1 and promote formation of tumor-initiating stem-like cells in livers of mice. Gastroenterology 2016;150:707–719. doi: 10.1053/j.gastro.2015.11.002

Copyright information

© Asian Pacific Association for the Study of the Liver 2016

Authors and Affiliations

  1. 1.Southern California Research Center for ALPD and Cirrhosis, Department of Molecular Microbiology and ImmunologyUniversity of Southern California Keck School of MedicineLos AngelesUSA

Personalised recommendations